Hisamitsu Pharmaceutical : Notification regarding Skin Care Cosmetics with Microneedle Technology
September 20, 2023 at 02:03 am EDT
Share
This material is an English translation of the press release announced on Sept. 20, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.
Sept. 20, 2023
Notification regarding Skin Care Cosmetics with Microneedle
Technology
Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President: NAKATOMI Kazuhide; hereinafter "Hisamitsu Pharmaceutical") announces that the development of microneedle cosmetics (hereinafter "The product") applying Hisamitsu's microneedle technology "HalDisc beauteⓇ" through a partnership with ALBION Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Shoichi Kobayashi;
hereinafter "ALBION").
The product is scheduled to be released by ALBION on Oct. 17 as a limited edition set*1 that includes the product.
HalDisc beauteⓇ is a technology consisting of Gel Patch containing water and beauty ingredients with a microneedle disc that does not damage the stratum corneum. While containing more beauty ingredients, it has excellent adhesion to the skin and moisture retention properties, and reduces skin irritation and pain during peeling.
HalDisc beauteⓇ Schematic diagram
Hisamitsu will continue to work on research and development of cosmetics, drugs, and other products utilizing microneedle technology, and promote the commercialization of microneedle technology as stated in the Seventh Medium-Term Management Policy*2. In addition, Hisamitsu will actively engage in partnering with other companies to create new value.
Representative: Shoichi Kobayashi, President and Chief Executive Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 20 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2023 06:02:04 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
